Skip to main content
. 2022 Oct 21;25(Suppl 6):e26009. doi: 10.1002/jia2.26009
Abstract P085 – Table 1. Characteristics of 359 experienced people living with HIV that started treatment with 3TC/DTG (265) or RPV/DTG (94).
Variables 3TC/DTG (n = 265) RPV/DTG (n = 94) Overall (n = 359) p‐value
Age, mean (±SD) 50.31±11.76 52.18±11.6 50.80±11.73 0.1835
Female gender, n (%) 53 (20.0) 29 (30.1) 82 (22.8) 0.0313
Caucasian ethnicity, n (%) 245 (92.5) 84 (89.4) 329 (91.6) 0.3521
Other ethnicity, n (%) 20 (7.5) 10 (10.6) 30 (8.4) 0.3521
Risk factor 0.0209
Sexual, n (%) 219 (82.6) 67 (71.3) 286 (79.7)
IDU, n (%) 25 (9.4) 19 (20.2) 44 (12.3)
HIV‐RNA detectable at baseline, n (%) 253 (95.5) 89 (94.7) 342 (95.3) 0.7564
HIV‐RNA undetectable at baseline, n (%) 12 (4.5) 5 (5.3) 17 (4.7) 0.7564
Previous regimens, n (%)
PI 92 (34.7) 32 (34.0) 124 (34.5) 0.906
NNRTI 75 (28.3) 46 (48.9) 121 (33.7) 0.0003
INSTI 80 (30.2) 22 (23.4) 102 (28.4) 0.2102
Anni ART, mean (±SD) 9.9 (5.4 to 14.9) 13.2 (7.1 to 20.6) 10.4 (5.8 to 16.8) 0.0015
CD4 cells/mmc, mean (±SD) 781.4 (359.8) 720.7 (304.2) 765 (346.2) 0.1469
CD4/CD8 ratio, mean (±SD) 1.09 (0.61) 0.97 (0.61) 1.05 (0.61) 0.1319
BMI, mean (±SD) 25.18 (3.69) 24.32 (3.84) 24.92 (3.75) 0.0744